Antigen Express
is a platform technology and
product-based company developing proprietary vaccine
formulations for active immunotherapy as well as disease
prevention.
In contrast to traditional
therapies, the goal of active immunotherapy is to
amplify the patients’ ability to fight specific disease
rather than targeting the diseased tissue or pathogenic
agent directly. The novel technologies being developed
at Antigen Express allows for robust and
antigen-specific stimulation of CD4+ T cells, a cell
type critical in the recognition of pathogens and
modulation of the immune response.
Antigen Express is developing these
technologies for application to the treatment of cancer,
infectious diseases, and other serious diseases. Our
most advanced vaccine utilizes a self-potentiating
peptide as an off-the-shelf product for active
immunotherapy of breast and prostate cancer.
ASCO: AE37 Peptide Vaccine May Help Prevent Breast
Cancer Recurrence
ANTIGEN EXPRESS CORPORATE FACTS SHEET
